Belharra and Genentech Enter into a Research Collaboration to Discover and Develop Small Molecules for Multiple Therapeutic Areas
Shots:
- Under the terms of the agreement, Belharra will receive $80M up front & is eligible for ~$2B in development & commercial milestones incl. tiered royalties in exchange for the worldwide rights to develop & commercialize small molecule therapies in oncology, immuno-oncology, autoimmune & neurodegenerative diseases
- In addition, Belharra received an option to co-develop certain oncology & autoimmune therapies through P-I & co-fund the remaining development in exchange for US cost/profit split & ex-US milestone payments & royalties
- Belharra will be responsible for the discovery & early preclinical development whereas Genentech will look after the target selection & late preclinical, clinical & commercial activities
Ref: Businesswire | Image: Belharra
Click here to read the full press release
Tags
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
